Alan Gregory Crawford, PA Dermatology Medicare: Accepting Medicare Assignments Practice Location: 24 Marks Road, Ocean Springs, MS 39564 Phone: 228-872-8873 Fax: 228-872-8876 |
Dr. Lindsey Zubritsky, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5935 Washington Ave, Ocean Springs, MS 39564 Phone: 228-215-0669 |
Eric Carl Torp, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2112 Bienville Blvd, Suite F1, Ocean Springs, MS 39564 Phone: 228-818-1850 Fax: 228-818-1807 |
Michele Haynie Hughes, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 5935 Washington Ave, Suite A, Ocean Springs, MS 39564 Phone: 228-215-0669 Fax: 228-215-0669 |
Dr. Thomas Calvin Garrott, MD Dermatology Medicare: Medicare Enrolled Practice Location: 24 Marks Road, Ocean Springs, MS 39564 Phone: 228-872-8873 Fax: 228-872-8876 |
News Archive
Researchers at Drexel University have identified the physical forces in red blood cells and blood vessels underlying the painful symptoms of sickle cell disease.
A team of scientists from the United States has recently explored the prevalence and transmission dynamics of the B.1.1.7 variant (UK variant) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the United States. The study reveals that because of 35-45% increased transmissibility, B.1.1.7 may soon become the US's dominant variant. The study is currently available on the medRxiv* preprint server.
Researchers from the Centers for Disease Control and Prevention have examined the potential for human exposure to prion diseases, looking at hunting, venison consumption, and travel to areas in which prion diseases have been reported in animals.
Men who reported permanent stress have a significantly higher risk of developing type 2 diabetes than men who reported no stress. This is the finding of a 35-year prospective follow-up study of 7,500 men in Gothenburg, by the University of Gothenburg, Sweden.
Merck KGaA, Darmstadt, Germany, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials today announced that the U.S. Food and Drug Administration has granted Fast Track designation for the development of evofosfamide (previously known as TH-302), administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally advanced unresectable pancreatic cancer.
› Verified 5 days ago